Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,516 across all filing types
Latest filing 2025-04-28 Proxy Solicitation & In…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
PROXY FORM FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON 30 MAY 2025 AT 10:00 A.M. (AND AT ANY ADJOURNMENT THEREOF)
Proxy Solicitation & Information Statement Classification · 91% confidence The document is a proxy form sent to shareholders to appoint proxies and vote on AGM resolutions (e.g., to receive audited statements, re-elect directors, approve mandates). This falls under Proxy Solicitation & Information Statement, as it solicits shareholder votes for the Annual General Meeting.
2025-04-28 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a formal Notice of Annual General Meeting, with agenda items, resolutions, proxy appointment instructions, and meeting particulars. It is sent to shareholders to provide information and request votes, matching the definition of a Proxy Solicitation & Information Statement rather than the meeting materials themselves (AGM-R) or the results. Therefore it should be classified as PSI.
2025-04-28 English
PROPOSALS FOR GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE SHARES, MANDATE TO GRANT OPTIONS AND RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a shareholder circular containing the “Letter from the Board,” explanatory statements on proposed resolutions (general mandates to buy back and issue shares, grant options, re-election of directors), and the formal Notice of Annual General Meeting, together with a proxy form. It is distributed to shareholders to solicit their votes and provide detailed background on each resolution at the AGM. This matches the Proxy Solicitation & Information Statement category (PSI) rather than the AGM materials themselves or a full report.
2025-04-28 English
2024 Environmental, Social and Governance Report
Environmental & Social Information Classification · 98% confidence The document is a comprehensive 2024 Environmental, Social and Governance (ESG) report for CSPC Pharmaceutical Group Limited. It covers governance structure, environmental management, social responsibility activities, ESG performance metrics, and aligns with the HKEX ESG Reporting Code and GRI guidelines. It is neither an annual financial report nor a brief announcement—it is a full ESG disclosure. Therefore, it matches the definition of Environmental & Social Information (Code: SR).
2025-04-28 English
2024 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2024' for CSPC Pharmaceutical Group Limited. It contains comprehensive sections including financial highlights, Chairman's statement, management discussion and analysis, corporate governance, and full consolidated financial statements (income statement, balance sheet, cash flows, and notes). This matches the definition of a 10-K (Annual Report). FY 2024
2025-04-28 English
VOLUNTARY ANNOUNCEMENT - SYH2068 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 85% confidence The document is a voluntary corporate announcement by CSPC Pharmaceutical concerning the approval of a new drug’s clinical trial. It does not present financial results, request shareholder votes, or relate to any specific specialized filing category (e.g., earnings release, share issuance, management change). As a miscellaneous Hong Kong exchange announcement about business development, it best fits the general Regulatory Filings category (RNS).
2025-04-25 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.